Asymmetric dimethylarginine and coronary collateral vessel development


Kocaman S. A. , ŞAHİNARSLAN A., BİBEROĞLU G., Hasanoglu A., Akyel A., Timurkaynak T., ...More

CORONARY ARTERY DISEASE, vol.19, no.7, pp.469-474, 2008 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 7
  • Publication Date: 2008
  • Doi Number: 10.1097/mca.0b013e328311d32b
  • Journal Name: CORONARY ARTERY DISEASE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.469-474
  • Keywords: asymmetric dimethylarginine, collateral, coronary artery disease, endothelial dysfunction, nitric oxide, L-ARGININE, ENDOTHELIAL DYSFUNCTION, DIABETES-MELLITUS, ARTERY-DISEASE, RISK, ANGIOGENESIS, EVENTS

Abstract

Introduction Nitric oxide (NO) plays a major role in collateral vessel development. Asymmetric dimethylarginine (ADMA) that is an endogenous inhibitor of NO synthesis may impair the effective coronary collateral vessel development. The aim of this study was to evaluate the relationship between plasma ADMA level and coronary collateral vessel development.